Neoadjuvant selpercatinib for advanced medullary thyroid cancer

BACKGROUND: Targeted kinase inhibitors have been increasingly utilized in the treatment of advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next generation selective RET inhibitors have been clinically validated, and selpercatinib was recently Food and Drug Admin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Head Neck
Main Authors: Jozaghi, Yelda, Zafereo, Mark, Williams, Michelle D., Gule‐Monroe, Maria K., Wang, Jennifer, Grubbs, Elizabeth G., Vaporciyan, Ara, Hu, Mimi I., Busaidy, Naifa, Dadu, Ramona, Waguespack, Steven G., Subbiah, Vivek, Cabanillas, Maria
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756223/
https://ncbi.nlm.nih.gov/pubmed/33169506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.26527
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados